4D Molecular Therapeutics(FDMT) - 2023 Q4 - Annual Results

Exhibit 99.1 4DMT Reports Full Year 2023 Financial Results and Operational Highlights • Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 • Positive interim clinical data for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease continue to demonstrate the potential of these prod ...